股腘动脉应用紫杉醇涂层支架后的死亡风险
该回顾性研究纳入日本4家医院1535例症状性下肢外周动脉疾病患者,比较紫杉醇涂层支架组285例与未暴露组1250例的死亡风险。倾向评分匹配及Cox模型显示两组全因死亡无显著差异(HR 0.89,95%CI 0.66-1.19,p=0.41),5年生存率分别为77.5%与73.7%。结论认为股腘动脉应用紫杉醇涂层支架5年内不增加死亡风险,且与剂量无关。
要点
- 紫杉醇涂层支架组与未暴露组全因死亡无显著差异(HR 0.89,p=0.41)。
- 3年生存率86.4% vs 87.7%,5年生存率77.5% vs 73.7%。
- 慢性肾衰竭和动脉钙化对紫杉醇支架与全因死亡的关联有显著交互作用。
核心结论
- 股腘动脉应用紫杉醇涂层支架5年内不增加死亡风险,且与剂量无关。
- 紫杉醇涂层支架是症状性下肢外周动脉疾病患者的安全治疗选择。
研究设计与样本
- 回顾性分析日本4家医院2010年1月至2016年12月收治的1535例症状性(Rutherford 2-4级)下肢外周动脉疾病患者。
- 紫杉醇涂层支架组285例(平均年龄73±8岁,男性213例),未暴露组1250例(平均年龄73±9岁,男性872例)。
- 采用倾向评分匹配平衡基线特征,并以倾向评分五分位分层的Cox比例风险模型分析死亡风险。
主要发现
- 3年总生存率紫杉醇涂层支架组86.4%,未暴露组87.7%;5年分别为77.5%与73.7%。
- 全因死亡风险两组无显著差异(HR 0.89,95%CI 0.66-1.19,p=0.41)。
- 死亡原因两组间无显著差异。
- 慢性肾衰竭(p=0.044)和动脉钙化(p=0.022)对紫杉醇涂层支架使用与全因死亡的关联有显著交互作用。
- 无亚组显示紫杉醇涂层支架与全因死亡风险增加相关,未见剂量依赖性。
临床怎么用
- 对于股腘动脉病变的症状性外周动脉疾病患者,可考虑使用紫杉醇涂层支架而不必担心5年内死亡风险增加。
- 合并慢性肾衰竭或动脉钙化的患者使用紫杉醇涂层支架时,死亡风险关联可能存在交互作用,需个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine if endovascular therapy (EVT) with paclitaxel-coated stents increases the mortality risk in patients with symptomatic lower limb peripheral artery disease (PAD). MATERIALS AND METHODS: A retrospective analysis was conducted of paclitaxel-coated stent use in the femoropopliteal segment of 1535 symptomatic (Rutherford category 2 to 4) patients treated between January 2010 and December 2016 at 4 hospitals in Japan. The risk of all-cause mortality was examined between the 285 patients (mean age 73±8 years; 213 men) treated with a paclitaxel-coated stent (PTX-coated group) and 1250 patients (mean age 73±9 years; 872 men) not exposed to a paclitaxel-coated device (PTX-free group) during EVT. Propensity score matching was employed to balance baseline characteristics. Cox proportional hazards models stratified on the quintiles of the propensity score were used to investigate paclitaxel-coated stent use and mortality risk as well as interactions among baseline variables and the main outcome. Interactions between a PXT-coated stent and subgroups of the PTX-free group (bare stent and angioplasty) were also investigated, as was the impact of paclitaxel dose on mortality risk. The results of regression analysis are reported as the hazard ratio (HR) and 95% confidence interval (CI). RESULTS: The 3-year overall survival estimates were 86.4% in the PTX-coated group vs 87.7% in the PTX-free group; the corresponding 5-year estimates were 77.5% vs 73.7%, respectively. There was no significant difference in all-cause mortality between the 2 groups (HR 0.89, 95% CI 0.66 to 1.19, p=0.41). The cause of death also showed no remarkable difference between the groups. Chronic renal failure (p=0.044) and arterial calcification (p=0.022) demonstrated a significant interaction effect on the association of the use of a PTX-coated stent with all-cause mortality. No subgroup demonstrated that the use of a paclitaxel-coated stent was associated with an increased risk of all-cause mortality. A dose dependency was not evident. CONCLUSION: Mortality risk following application of a PTX-coated stent did not increase over 5 years, irrespective of the dose. A PTX-coated stent for femoropopliteal lesions in PAD patients is a safe treatment option.
引用
- Katsuki T, Takahara M, Soga Y, et al. Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions. J Endovasc Ther. 2019. PMID: 31431154. doi:10.1177/1526602819870309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。